AVTX: 406% | Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
XLO: 399% | Xilio Therapeutics shares are trading higher after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.
BDRX: 46% | Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers